GPX1 and chronic myelogenous leukemia, BCR-ABL1 positive: Incubation of another CML cell line, MEG-01 [18] with a cytostatic dose of imatinib (300 nM) for 7 days resulted in a 1.6 fold increase in activity (Fig. 3A) and a 4 fold increase in GPx-1 protein levels (Fig. 3B).